6个月近12亿元营收,虽赶不上“前三小龙”,但君实生物跟自己比赢了

医药研究社
Aug 27

肿瘤治疗“长坡厚雪”。来源|医药研究社每每提到君实生物,不少投资者都会替它感到惋惜:这家药企曾与百济神州、恒瑞医药、信达生物并肩,合称为PD-1“四小龙”,如今却跟不上大队伍。不过,若“自己跟自己比”,近年君实生物着实进步了不少。财报显示,2024年上半年,君实生物实现营业收入7.86亿元,同比增加17.37%;净亏损6.45亿元,同比缩窄35.34%。今年上半年,公司实现营业收入11.68亿元,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10